A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Key Inclusion Criteria: * BMI ≥ 22kg/m\^2 * Type 2 diabetes with HbA1c between 6.5% and 10.0% * Documented symptomatic chronic heart failure (NYHA II-IV) * Plasma NT-proBNP \> 300pg/ml * eGFR ≥ 45ml/min/1.73m\^2 (calculated by MDRD) Key Exclusion Criteria: * Pregnant or nursing (lactating) women * Type 1 diabetes, monogenic diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes * History of ketoacidosis, lactic acidosis, or hyperosmolar coma * Symptomatic genital infection or UTI within 4 weeks of screening * Myocardial infarction, stroke, surgery for heart disease, percutaneous coronary intervention within 3 months of randomization * Unstable angina within 3 months of screening * Isolated right HF due to pulmonary disease * Patients with a mean sitting systolic blood pressure ≤ 100mmHg, at randomization * History of lower limb amputation * Diabetic foot ulcer at screening